BioXcel reports Q1 net loss $12.7M; FDA sets Nov 14 PDUFA for at-home IGALMI

BioXcel Therapeutics, Inc.

2026-Q1 EPS reported -$0.54 revenue$206,000

FDA accepted sNDA for IGALMI at-home use in agitation associated with bipolar/schizophrenia; PDUFA date Nov 14, 2026.
Net revenue $206K (up 23% YoY from $168K); net loss $12.7M vs $7.3M in Q1 2025.
Engaged MTS Health Partners to explore strategic options including sale, merger, or collaboration.
Cash and equivalents $17.2M as of Mar 31, 2026; company in compliance with credit covenants.
R&D down to $3.0M from $4.6M due to SERENITY trial completion; SG&A up to $7.2M from $5.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BioXcel Therapeutics, Inc. reported the three months ended March 31, 2026 results: revenue $206,000, net income net loss of $12.7 million.

Period: the three months ended March 31, 2026
Revenue: $206,000
Net income: net loss of $12.7 million
Result: reported results

Exact text from the filing

FDA approval in an adjacent indication, which is further reinforcing the need in this therapeutic area. First Quarter 2026 Financial Results Net revenue from IGALMI® was $206,000 for the first quarter of 2026, compared to $168,000 for the same period in 2025. The Company is focused on preparing for IGALMI’s launch in the at-home setting and maintaining

View on SEC.gov

Browse all earnings releases →

BioXcel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-061773

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.